

Title (en)
SOLID PHARMACEUTICAL COMPOSITIONS FOR TREATING HCV

Title (de)
FESTE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON HCV

Title (fr)
COMPOSITIONS PHARMACEUTIQUES SOLIDES POUR LE TRAITEMENT DU VHC

Publication
EP 3324941 A1 20180530 (EN)

Application
EP 16745584 A 20160718

Priority

- US 201562193639 P 20150717
- US 201662295309 P 20160215
- US 201615192211 A 20160624
- US 2016042806 W 20160718

Abstract (en)
[origin: WO2017015211A1] The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

IPC 8 full level
A61K 9/14 (2006.01); **A61K 9/20** (2006.01); **A61K 9/24** (2006.01); **A61K 31/454** (2006.01); **A61K 31/498** (2006.01); **A61P 31/14** (2006.01)

CPC (source: EP IL KR)
A61K 9/146 (2013.01 - EP IL KR); **A61K 9/2027** (2013.01 - EP IL KR); **A61K 9/2054** (2013.01 - EP IL KR); **A61K 9/209** (2013.01 - EP IL KR); **A61K 31/454** (2013.01 - EP IL KR); **A61K 31/498** (2013.01 - IL); **A61K 31/4985** (2013.01 - EP KR); **A61P 1/16** (2018.01 - EP); **A61P 31/14** (2018.01 - EP); **A61P 31/18** (2018.01 - EP)

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2017015211 A1 20170126; AU 2016296709 A1 20180208; AU 2016296709 B2 20211111; AU 2016296709 C1 20220224; BR 112018000982 A2 20180911; CA 2992722 A1 20170126; CA 2992722 C 20231017; CL 2018000138 A1 20180713; CN 108024964 A 20180511; CN 108024964 B 20220503; CO 2018000391 A2 20180612; CR 20180088 A 20180524; DO P2018000024 A 20180415; EA 201890334 A1 20180629; EC SP18008411 A 20180430; EP 3324941 A1 20180530; HK 1255203 A1 20190809; IL 256945 A 20180329; IL 256945 B1 20230601; IL 256945 B2 20231001; JP 2018520185 A 20180726; JP 2022141719 A 20220929; JP 7133466 B2 20220908; JP 7472199 B2 20240422; KR 20180025317 A 20180308; KR 20240108528 A 20240709; MX 2018000746 A 20180815; PE 20180609 A1 20180409; PH 12018500132 A1 20180723; RU 2018105849 A 20190819; RU 2018105849 A3 20191213; SG 10202002900Y A 20200528; ZA 201801082 B 20181219

DOCDB simple family (application)
US 2016042806 W 20160718; AU 2016296709 A 20160718; BR 112018000982 A 20160718; CA 2992722 A 20160718; CL 2018000138 A 20180117; CN 201680052931 A 20160718; CO 2018000391 A 20180116; CR 20180088 A 20160718; DO 2018000024 A 20180117; EA 201890334 A 20160718; EC PI201808411 A 20180206; EP 16745584 A 20160718; HK 18114330 A 20181108; IL 25694518 A 20180116; JP 2018501944 A 20160718; JP 2022107289 A 20220701; KR 20187004422 A 20160718; KR 20247020998 A 20160718; MX 2018000746 A 20160718; PE 2018000084 A 20160718; PH 12018500132 A 20180116; RU 2018105849 A 20160718; SG 10202002900Y A 20160718; ZA 201801082 A 20180216